AZN vs CELC: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

AZN is the larger of the two ($272.37B market cap): the incumbent the market prices for continued execution (15.52x forward earnings, beta 0.16). CELC is the smaller challenger ($2.65B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, CELC fits: analysts expect its revenue to rise 1981% next year, against 6% for AZN. If you believe in profit, AZN fits: it is expected to make money next year (15.52x forward earnings), while CELC is still expected to post a loss.

AZN vs CELC: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricAZNCELCWhat it tells you
Market cap$272.37B$2.65BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E15.52-10,835.00Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.160.13Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range37% of range1% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how AZN and CELC affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and CELC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and CELC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does AstraZeneca (AZN) do?

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.

Full AZN guide

What does Celcuity (CELC) do?

Celcuity Inc. is a Minneapolis-based biotechnology company focused on targeted therapies for solid tumors. Its lead product, gedatolisib, is a pan-PI3K/AKT/mTOR (PAM) inhibitor for HR+/HER2- advanced breast cancer. Unlike single-node inhibitors such as alpelisib, capivasertib, and everolimus, gedatolisib is designed to block the whole pathway at once. The registrational Phase 3 VIKTORIA-1 trial hit its primary endpoint, with gedatolisib combination regimens roughly doubling progression-free survival versus alpelisib plus fulvestrant in the PIK3CA-mutant cohort, results presented at ASCO. On July 14, 2026, three days ahead of its PDUFA goal date, the FDA approved gedatolisib as REVTORPYK for adults with HR+/HER2-, PIK3CA wild-type, locally advanced or metastatic breast cancer that progressed after at least one line of endocrine therapy in the metastatic setting, used with fulvestrant with or without palbociclib. Celcuity submitted a supplemental NDA for the PIK3CA-mutant population in August 2026, announced US commercial availability on September 30, 2026, and on November 9, 2026 said the FDA had accepted the sNDA with a PDUFA goal date of June 25, 2027.

Full CELC guide

AZN vs CELC: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
  • CELC drivers: REVTORPYK launch execution; The PIK3CA-mutant label.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For CELC, celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA (goal date June 25, 2027), or disappointing later cohort data could sharply reduce the value the market assigns.

AZN or CELC: which should you pick?

If the story you believe is AZN's (Oncology franchise and the $80 billion ambition), AZN is the more direct way to own it; if it is CELC's (REVTORPYK launch execution), CELC is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZN and CELC guides.

AZN vs CELC: the full fundamentals

AZN. AstraZeneca trades at about 25 times trailing reported earnings but about 15.5 times forward earnings, a gap that reflects heavy amortisation and one-off charges in reported profit and consensus for 2026 EPS near $10.12 rising to about $11.32 in 2027. The forward multiple has edged up from about 14.6 in October as the shares recovered, but it still sits near the low end of where a growth-oriented large-cap pharma usually trades, so the valuation reflects more caution about the 2032 patent cliff than enthusiasm for the $80 billion 2030 goal. Figures are approximate and tied to the asOf date; confirm live numbers before acting.

CELC. Because Celcuity has only just begun selling REVTORPYK, standard multiples like price-to-earnings or price-to-sales still do not apply, and the market cap of about $2.7 billion reflects the expected value of the launch and label expansion. Debt of about $755 million now exceeds cash of about $643 million, and management expects the cash to fund operations through 2029. Analysts' mean target near $151 across 13 analysts sits far above the November 20, 2026 price of $54.42, a gap that reflects how differently forecasts and the market are reading the launch.

Headline figures (approximate, November 2026): AZN shows revenue (ttm) About $62.4 billion; Q3 2026 revenue about $16.2 billion, up roughly 7% year over year, net income (ttm) About $11.0 billion, a net margin near 18%, with gross margin near 82% and operating margin near 26%, eps Q3 2026 EPS $1.00 vs about $1.15 expected; trailing reported EPS about $7.07, p/e About 25x trailing reported earnings, about 15.5x forward; CELC shows revenue (ttm) ~$0 (first shipments September 30, 2026); Q4 2026 consensus ~$13.6M, market cap ~$2.7B, share price (nov 20, 2026) ~$54, down ~46% YTD, q3 2026 net loss / adjusted eps ~$73.3M / -$1.21 vs -$1.53 estimate.

The bottom line: AZN vs CELC

AZN and CELC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AZN and CELC exposure against your real portfolio. It is not an investment adviser.

Wondering how AZN or CELC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about AstraZeneca

Ask Walnut's AI anything about AZN and see how it fits what you own.

FAQ

What is the difference between AZN and CELC?

+

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. Celcuity Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is AZN or CELC the better stock?

+

Neither is universally better. AZN is the larger incumbent; CELC is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, AZN or CELC?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both AZN and CELC?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of AZN vs CELC?

+

AZN: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. Generic and biosimilar erosion is already visible, with first generics to Farxiga cleared in 2026. Pipeline risk is constant, since late-stage trial failures such as a disappointing AVANZAR result can erase billions in expected value quickly. China, about a tenth of revenue, carries added uncertainty after the company's former China head was indicted in a compliance case that drew investor lawsuits. Drug pricing policy, US tariffs and currency swings add further volatility, and the balance sheet carries about $34 billion of debt against about $8 billion of cash. As a large-cap pharma the stock can still fall sharply on a single disappointing readout or regulatory decision, as its slide from a 52-week high near $213 to a low near $153 shows. The Q3 2026 EPS shortfall against consensus is a reminder that quarterly earnings can disappoint even as revenue grows. CELC: Celcuity is still essentially a single-product company, so a slow launch, a delay or narrow outcome on the PIK3CA-mutant sNDA (goal date June 25, 2027), or disappointing later cohort data could sharply reduce the value the market assigns. The stock fell about 17% in the month to November 20, 2026 and is down about 46% for the year despite approval and an accepted second filing, which shows how harshly it is being judged on early commercial signals. It lost about $256 million over the trailing twelve months, spending is rising with the launch, and stockholders' equity turned negative at September 30, 2026. The June 2026 convertible offering removed near-term funding pressure (about $643 million of cash at September 30, a runway management puts through 2029), but it also added about $575 million of convertible debt that can dilute holders if converted at about $124.53 a share, and total debt on the balance sheet is about $755 million. Commercial uptake faces entrenched and newly approved competitors, payer and pricing pressure, and the operational challenge of a first launch. The stock has been volatile and can gap on single events, which is characteristic of small biotech rather than a defect specific to this name.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AZN or CELC; figures are approximate and dated (as of November 2026). Verify current data before investing.